Fundraising Fox

Accession Therapeutics

2 known investors

Accession Therapeutics is a biotech company developing immuno-oncology cancer treatments based on its stealth virus platform, Trocept, which engineers a viral point of entry into cancer cells while bypassing healthy cells. Its lead drug candidate is in a Phase 1 clinical trial (ATTEST), with a pipeline of additional targeted cancer therapies in development.

BiotechHealthtech

Founders & leadership

BJ
Bent JakobsenCEO

Investors · 2

iGlobe PartnersSingapore · $600K – $6M
Birk VenturereportedOslo

In the news

Accession Therapeutics awarded €7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapyaccessiontherapeutics.com · Mar 2026Accession Therapeutics raises £30.5m | HealthInvestor UKhealthinvestor.co.uk · Dec 2025Accession Therapeutics raises £30.5 million ($40 million USD) to advance TROCEPT immunotherapy platformaccessiontherapeutics.com · Dec 2025Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidateaccessiontherapeutics.com · Apr 2024Accession Therapeutics raises funding - ARC Oxfordarcgroup.io · Nov 2022Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trialsaccessiontherapeutics.com · Nov 2022

Frequently asked questions

What does Accession Therapeutics do?
Accession Therapeutics is a biotech company developing immuno-oncology cancer treatments based on its stealth virus platform, Trocept, which engineers a viral point of entry into cancer cells while bypassing healthy cells. Its lead drug candidate is in a Phase 1 clinical trial (ATTEST), with a pipeline of additional targeted cancer therapies in development.
Who are Accession Therapeutics's investors?
Accession Therapeutics's investors include iGlobe Partners, Birk Venture.